Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia



Status:Recruiting
Healthy:No
Age Range:6 - Any
Updated:3/22/2019
Start Date:February 2016
End Date:June 2024
Contact:Jill Dolgin, PharmD
Email:advocacy@agtc.com

Use our guide to learn which trials are right for you!

A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 (rAAV2tYF-PR1.7-hCNGB3) in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene

This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of
rAAV2tYF-PR1.7-hCNGB3 administered to one eye by subretinal injection in individuals with
achromatopsia caused by mutations in the CNGB3 gene. The primary study endpoint will be
safety and the secondary study endpoint will be efficacy.

This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of
rAAV2tYF-PR1.7-hCNGB3 administered to one eye by subretinal injection in individuals with
achromatopsia caused by mutations in the CNGB3 gene. The primary study endpoint will be
safety and the secondary study endpoint will be efficacy.

Subjects will be enrolled sequentially in four groups. Subjects in Groups 1, 2 and 3 will be
at least 18 years of age and will receive a lower, middle or higher dose of study agent.
Subjects in Group 4 will be at least 6 years of age and will receive the maximum tolerated
dose identified in Groups 1, 2 and 3.

Safety will be monitored by evaluation of ocular and non ocular adverse events and hematology
and clinical chemistry parameters. Efficacy parameters will include visual acuity, light
discomfort testing, color vision, static visual field, ERG, adaptive optics retinal imaging
and OCT.

Inclusion Criteria include:

1. Retinal disease consistent with a diagnosis of achromatopsia and documented mutations
in both alleles of the CNGB3 gene;

2. At least 18 years of age for Groups 1, 2 and 3 and at least 6 years of age for Group
4;

3. Able to perform tests of visual and retinal function;

4. Visual acuity in the study eye not better than 55 ETDRS letters (Snellen equivalent
20/80) based on the average of two examinations at the baseline visit;

5. Acceptable laboratory parameters;

6. For females of childbearing potential: A negative pregnancy test within 2 days before
administration of study agent.

Exclusion Criteria include:

1. Refractive error of ≥ -8.00 diopters (spherical equivalent) of myopia in the study
eye;

2. Evidence of degenerative myopia regardless of the refractive error in the study eye;

3. Pre-existing eye conditions that would contribute to vision loss in either eye or
increase the risk of subretinal injection in the study eye.
We found this trial at
9
sites
900 Northwest 17th Street
Miami, Florida 33136
Principal Investigator: Byron L Lam, MD
Phone: 305-326-6021
?
mi
from
Miami, FL
Click here to add this to my saved trials
243 Charles St
Boston, Massachusetts 02114
(617) 523-7900
Massachusetts Eye & Ear Infirmary Whether you see our physicians at Mass. Eye and Ear's...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chicago, Illinois 60608
Principal Investigator: Gerald A Fishman, MD
Phone: 312-447-3254
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cincinnati, Ohio 45242
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
2351 Erwin Road
Durham, North Carolina 27710
?
mi
from
Durham, NC
Click here to add this to my saved trials
Gainesville, Florida 32607
Principal Investigator: Christine N Kay, MD
Phone: 352-371-2800
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
8701 W Watertown Plank Rd
Milwaukee, Wisconsin
(414) 955-8296
Principal Investigator: Joseph J Carroll, PhD
Phone: 414-955-2052
Medical College of Wisconsin The Medical College (MCW) of Wisconsin is a major national research...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
Portland, Oregon 97239
Principal Investigator: Mark A Pennesi, MD
Phone: 503-494-0020
?
mi
from
Portland, OR
Click here to add this to my saved trials